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Abstract
Antimicrobial resistance (AMR) is an increasing problem. The prevalence of antimicrobial resistance in general practice patients
is expected to be relatively high in Rotterdam, the Dutch city with the largest proportion non-Western immigrants. The aim of this
study was to assess the prevalence of antibiotic-resistant uropathogens (Escherichia coli, Klebsiella pneumoniae, and Proteus
mirabilis) in general practices in Rotterdam, and to find a possible association between the prevalence of antibiotic-resistant
E. coli and age, gender, and socioeconomic status (SES). A retrospective analysis was performed of urine samples from general
practice patients in 2016. The prevalence of AMR in uropathogens was compared with national resistance data, as was the
prevalence of highly and multidrug resistant and extended spectrum β-lactamase (ESBL) producing E. coli and K. pneumoniae.
Univariate logistic regression was used to study associations between antibiotic-resistant E. coli and age, gender, and SES area
score. No clinically relevant differences were observed in the prevalence of antibiotic-resistant uropathogens in Rotterdam
compared with the national prevalence. For E. coli and K. pneumoniae, the prevalence was 3.6% for ESBL production (both
pathogens together), while the prevalence ranged between 4.2%–5.0% for high resistance and between 1.2%–3.3% for multidrug
resistance. Ciprofloxacin-resistant E. coli was significantly associated with higher age. Although Rotterdam has a high percent-
age of non-western immigrants and a low SES, AMR is low among general practice patients. This indicates that adherence to
national guidelines in general practice enables maintenance of low AMR, even in high-risk populations.
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Introduction
Antimicrobial resistance (AMR) is an increasing public health
problem. Although the prevalence of antibiotic-resistant mi-
croorganisms in the Netherlands is low compared with other
countries in Europe and worldwide, resistance is increasing
[1]. National data on the prevalence of antibiotic-resistant mi-
croorganisms are published annually in NethMap [2]. The
data are obtained from the Infectious Diseases Surveillance
Information System-Antimicrobial Resistance (ISIS-AR), a
national surveillance system among microbiological laborato-
ries that send their data—which are routinely obtained from
patient samples—for analysis to the National Institute of
Public Health and the Environment (RIVM) [2]. The results
from urine samples from general practice (GP) patients with
(putative) urinary tract infections (UTI) are also included in
NethMap. These samples are mainly from patients after treat-
ment failure of initial therapy according to the National
Guidelines (NHG) [2, 3]. Risk factors contributing to the car-
riage of or infection with an antibiotic-resistant microorgan-
ism in the community include travel to foreign countries, fre-
quent use of antibiotics, being born outside the Netherlands,
recent (foreign) hospitalization, higher age, and comorbidity
[4–8].
The population of Rotterdam—the second largest city in
the Netherlands—consists of 38% non-Western immigrants,
mostly from Suriname, Turkey, Morocco, and other countries
[9]. Theymay travel often to their home country to visit family
and friends and may have an increased risk of coming into
contact with antibiotic-resistant microorganisms.
Furthermore, they have a higher morbidity (22% more loss
of healthy life years due to morbidity than the native Dutch
population), which can lead to frequent use of antibiotics, one
of the main drivers of AMR [10]. Besides having the highest
proportion of non-Western immigrants, Rotterdam on average
has a lower socioeconomic status (SES) than the Netherlands
in general [11]. A low individual SES can be considered an
indicator of poor immune regulation and impoverished health
condition, and thus a risk factor for AMR [12, 13]. In addition,
patients with antibiotic-resistant infections are more likely to
be unemployed, to have a lower educational attainment, and a
lower income [14]. Due to the high proportion of immigrants
and the low SES score, it could be expected that the preva-
lence of AMR in the Rotterdam population is higher than the
national AMR prevalence reported in NethMap.
Until 2017, no data were publicly available on the preva-
lence of antibiotic-resistant microorganisms among GP pa-
tients in Rotterdam. The objectives of this study were firstly
to establish the prevalence of antibiotic-resistant uropathogens
from GP patients in Rotterdam, i.e., Escherichia coli (E. coli),
Klebsiella pneumoniae (K. pneumoniae), and Proteus
mirabilis (P. mirabilis), and the prevalence of highly and mul-
tidrug resistant and extended spectrum β-lactamase (ESBL)–
producing E. coli and K. pneumoniae. Secondly, we aimed to
assess the association between the prevalence of antibiotic-
resistant E. coli and age, gender and SES score. We
hypothesised that the prevalence of antibiotic resistance in
Rotterdam is higher than the national prevalence of AMR,
due to its higher proportion of non-Western immigrants and
the lower SES score.
Materials and methods
Design and procedures
We conducted a retrospective analysis of microbiological re-
sults from the GP laboratory (Star-SHL) of urine samples
submitted in 2016. The dataset consisted of the four-digit
postal codes of both the GP and the patient, an encrypted
unique patient code, year of birth and gender of the patient,
date the urinary samples were received, and the microbiolog-
ical culture results. The culture results included the following:
the isolated micro-organism, the antibiotic susceptibility, and
the presence of ESBL.
A urine culture was considered positive when > 10e3 col-
ony forming units per ml of one bacterial species were detect-
ed. The presence of ≥ 2 bacterial species was considered
mixed flora and was not included in the analyses. Antibiotic
susceptibility was tested using the VITEK® 2 COMPACT
system (Biomerieux, Lyon) and interpreted according to the
EUCAST guidelines of 2016 [15]. The resistance percentages
of the most common uropathogens, i .e . , E. coli ,
K. pneumoniae, and P. mirabilis were determined for amoxi-
cillin, co-amoxiclav, cefuroxime, cefotaxime, ceftazidime,
ciprofloxacin, gentamicin, tobramycin, fosfomycin, trimetho-
prim, co-trimoxazole, and nitrofurantoin. Aminoglycosides
(gentamicin and tobramycin) were only included for compar-
ative purposes with NethMap. Because we did not have access
to the underlying data of NethMap, we could not calculate
statistical significance of differences between the prevalence
of the Rotterdam region and the national prevalence reported
in NethMap. Therefore, we applied the term that NethMap
uses to compare trends over time, clinically relevant differ-
ences [2]. This is defined by NethMap as a difference of ≥
5% for prevalences ≥ 10%, and of ≥ 2.5% for prevalences <
10%. A difference in resistance between Star-SHL data and
the NethMap data was considered clinically relevant accord-
ing to this definition, with the NethMap prevalence data serv-
ing as reference [2]. One isolate per patient per uropathogen,
and only the first isolate in 2016, was included in the final
analysis to avoid bias of repeated isolates of a patient. The
production of ESBL and the prevalence of highly resistant
microorganisms (HRMO) and multidrug resistance in E. coli
and K. pneumoniae were determined according to the criteria
used in NethMap [2]. ESBL production was determined as
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resistant to cefotaxime/ceftriaxone and/or ceftazidime as indi-
cator agents. HRMO was defined as ESBL positive, or resis-
tant to both fluoroquinolones (ciprofloxacin) and aminoglyco-
sides (gentamicin or tobramycin). Multidrug resistance was
defined as resistant to co-amoxiclav and ciprofloxacin and
co-trimoxazole. Because E. coli and K. pneumoniae are the
most common Enterobacteriaceae for determining ESBL pro-
duction, HRMO, and multidrug resistance, we used these in
our study. We excluded the prevalence of resistance in mixed
specimens, due to the absence of sensitivity data in these
mixed specimens.
Statistical methods
We calculated the associations between antibiotic-resistant
E. coli and age, gender, and SES area score using univariate
logistic regression analysis. We used the prevalence of
antibiotic-resistant E. coli as the outcome variable in the re-
gression analyses because it was the most common
uropathogen. Age was calculated in years (2016 minus the
year of birth). We included age as a dichotomous variable
(< 70 years and ≥ 70 years). We analysed gender as a binary
outcome variable (male/female). Because individual SES was
unknown, we used SES score at the neighbourhood level
(‘SES area score’) as a proxy for the individual SES. SES area
score is calculated by the Social and Cultural Planning Office
(SCP) and is based on the average income and the percentage
of low-educated people, unemployed people, and people with
a low income per neighbourhood/postal code. According to
the SCP, a SES area score of less than − 1 is a low score, a
score between − 1 and + 1 is average, and a score of more than
1 is considered as high [16]. Only the postal codes 3000–3089
of the city of Rotterdam were included in our analyses. We
considered p values < 0.05 as statistically significant. To re-
duce the risk of a type I error, we adjusted the p values for
multiple testing using the Holm-Bonferroni method.
Statistical descriptive analyses and univariate logistic regres-
sion were performed using the data.table-, glm-, and the dplyr
function in RStudio 1.1.383 [17].
Results
In 2016, 7966 urine samples were submitted to Star-SHL from
patients from Rotterdam. Of these, 21.8% (n = 1734) were
culture positive, and 2.7% (n = 218) were mixed flora. The
median age of the patients was higher in men (75 years) than
in women (69 years), and the male/female ratio was 20:80.
More than 5000 patients (65.6%, n = 5226) had a low SES
area score, 27.0% (n = 2151) and 7.4% (n = 589) had an aver-
age and high SES area score respectively.
The age of patients with positive cultures ranged from 15 to
103 years, of whom 50.0% belonged to the age group of ≥
70 years. E. coli was the most common uropathogen (n =
1130; 65%), followed by K. pneumonia (n = 167; 10%) and
P. mirabilis (n = 120; 7%). The remaining 18% (n = 317) in-
cluded 54 other species, such as Pseudomonas aeruginosa,
Enterococcus spp., and Klebsiella oxytoca.Most E. coli–pos-
itive samples were from patients with a low SES area score
(n = 701, 62.0%) followed by a middle SES area score (n =
346; 30.6%) and high SES area score (n = 83; 7.4%).
The highest prevalence of resistance among E. coli was to
amoxicillin (41.0%), among K. pneumoniae to fosfomycin
(32.0%), and among P. mirabilis to trimethoprim (31.0%)
(Table 1). There were no clinically relevant differences in
the prevalence of resistance to the antibiotics tested between
isolates from Rotterdam and the national data, except for
tobramycin in P. mirabilis that was higher in Rotterdam
(7.0%) than in NethMap (3.0%). The prevalence of ESBL
producing E. coli and K. pneumoniae together in Rotterdam
was 3.6% and comparable with the national prevalence of
3.1% for all Enterobacteriaceae (Table 2). The prevalence of
HRMOwas 5.0% in E. coli and 4.2% in K. pneumoniae com-
pared with both 5.0% in national data. Multidrug resistance
was 3.3% in E. coli and 1.2% in K. pneumoniae, compared
with a national prevalence of 3.0% and 2.0%, respectively.
When age was dichotomised (< 70 years and ≥ 70 years),
higher age was associated with ciprofloxacin and
nitrofurantoin resistant E. coli (OR 1.86; 95% CI 1.27–2.73;
p = 0.001 and OR 4.11; 95% CI 1.50–14.41; p = 0.01, respec-
tively) (Table 3). However, after adjustment for multiple test-
ing using the Holm-Bonferroni method, higher age was only
significantly associated with ciprofloxacin resistance
(Bonferroni corrected p = 0.03). A low SES area score was
associated with higher resistance to cefuroxime (OR 4.93;
95% CI 1.51–30.35; p = 0.03), but after adjustment for multi-
ple testing, this effect was not statistically significant. Gender
was not associated with antibiotic resistant E. coli.
Discussion
This study provides insight into the prevalence of AMR of
E. coli, K. pneumoniae, and P. mirabilis in general practice
in Rotterdam. The prevalence of AMR among these microor-
ganisms was in general comparable with the national data in
NethMap 2016. Higher age was significantly associated with
E. coli resistance for ciprofloxacin. We found no association
between gender or SES area score and resistant E. coli.
We hypothesised that the prevalence of antibiotic resistance
in Rotterdam would be higher than the national prevalence of
AMR in 2016, due to the higher proportion of non-Western
immigrants and the lower SES area score. However, our re-
sults do not support this hypothesis. The reasons for the
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rejection of our hypothesis remain unclear. Furthermore, we
found no association between AMR and SES. Perhaps the use
of SES area scores instead of individual SES scores underes-
timates a possible association. With area scores, individual
differences in SES are levelled out. In addition, we have no
data about migration status, travel behaviour, and other indi-
vidual socioeconomic factors. Pini et al. [14] speculated that
there are several pathways of lower socioeconomic conditions
that could lead to a higher occurrence of infectious diseases,
such as affected living conditions due to poor housing,
overcrowding, poor nutrition, unsatisfactory hygiene, un-
healthy lifestyle, scarce health education and knowledge,
and reduced immunisation.We would need to link laboratorial
data to individual migration and socioeconomic factors to fur-
ther explore the association between AMR and possible risk
factors.
A strength of our study is that it includes many positive
urine cultures (more than 1700). It is the first study that pre-
sents data on the prevalence of AMR and the associations
between resistance and risk factors age, gender, and SES area
Table 1 Prevalence of
antimicrobial resistance for three
different uropathogens compared
with the national prevalence in
2016













69 years 66 years 74 years 73 years 79 years 75 years
Antibiotic
Amoxicillin 41% 39% – – 19% 21%
Co-amoxiclav 17% 20% 11% 10% 5% 5%
Cefuroxime 9% 7% 14% 14% 2% 1%
Cefotaxime 3% 3% 5% 5% 1% 1%
Ceftazidime 2% 2% 5% 4% 0% 0%
Ciprofloxacin 11% 9% 4% 4% 6% 7%
Gentamicin 3% 4% 4% 2% 7% 5%
Tobramycin 3% 4% 4% 3% 7%b 3%b
Fosfomycin 2% 1% 32% 32% 20% 17%
Trimethoprim 26% 25% 20% 22% 31% 35%
Co-trimoxazole 25% 23% 11% 11% 28% 28%
Nitrofurantoin 2% 2% – – – –
a Age > 12 years
b Italicized reported figures: the difference in resistant P. mirabilis against tobramycin between Star-SHL and
NethMap is clinically relevant; i.e. absolute difference of ≥ 2.5% for prevalences < 10%
Table 2 Prevalence of ESBL, HRMO and multidrug resistance compared with the national prevalence in 2016
Rotterdam Netherlands
E. coli + K. pneumonia together (n = 1297) All Enterobacteriaceae (n = 101,330)
ESBLa 3.6%b 3.1%c
E. coli (n = 1130) K. pneumoniae (n = 167) E. coli (n = 57,948)d K. pneumoniae (n = 7801)d
HRMOe 5.0% 4.2% 5.0% 5.0%
Multidrug resistancef 3.3% 1.2% 3.0% 2.0%
ESBL Extended spectrum beta-lactamase
HRMO Highly Resistant Microorganisms
a ESBL was determined as resistant to cefotaxime (or ceftriaxone) and/or ceftazidime
bDetermined for E. coli and K. pneumonia together
c Determined for all Enterobacteriaceae
dAge > 12 years
e HRMO was defined as resistant to cefotaxime/ceftriaxone and/or ceftazidime as indicator agents for the production of ESBL, or resistant to both
fluoroquinolones (ciprofloxacin) and aminoglycosides (gentamycin or tobramycin) in E. coli and K. pneumonia
fMultidrug resistance was defined as resistant to co-amoxiclav and ciprofloxacin and co-trimoxazole in E. coli and K. pneumoniae
Eur J Clin Microbiol Infect Dis
score in GP patients in Rotterdam. A limitation is that we only
included data from GPs who are affiliated with the Star-SHL
laboratory, which is estimated to be approximately 65% of all
GPs in Rotterdam. We have no information on the number of
urine samples that were examined in this laboratory compared
with the total number of patients who visited their GP with
UTI complaints. The resistance data obtained are most likely
from patients not responding to the first (and possibly second)
empiric therapy choice nitrofurantoin, fosfomycin, and tri-
methoprim, which is comparable with NethMap. However,
these patients are not representative of the resistance in “un-
selected” samples of GP patients with a UTI.
The prevalence of antibiotic-resistant uropathogens in
Rotterdam was comparable with the national data. The only
difference, namely tobramycin-resistant P. mirabilis (7.0%
versus 3.0%), can be explained by different cutoff values.
The NethMap data are based on the EUCAST guidelines,
i.e. a cutoff MIC value > 4 mg/L for resistance of
Enterobacteriaceae to aminoglycosides including tobramycin.
STAR-SHL used cutoff values of > 2 mg/L as resistance cri-
terion due to the phenotype interpretation of the expert system
of VITEK, resulting in a higher resistance prevalence than
NethMap.
The prevalence of ESBL among E. coli and
K. pneumoniae in our study (3.6%) was comparable
with the national data. Other studies reported preva-
lences ranging from 4.5 to 19.1% [18–25]. It should
be noted, however, that these other studies have includ-
ed populations that are not comparable with our patient
population. Van der Bunt et al. [18] and Koningstein
et al. [19] included children and adults at day-care cen-
tres and also included Enterobacter cloacae; Wielders
et al. [20] and Huijbers et al. [21] investigated a popu-
lation in areas with many livestock and broilers, where
Wielders included Enterobacter spp., Citrobacter
freundii, Morganelli morganii, and Hafnia alvei for fur-
ther analysis if they displayed an ESBL phenotype.
Reuland et al. [22, 23] included patients with and with-
out gastrointestinal complaints and included one
Shigella sonnei isolate. In these studies, faecal samples
were examined. Paltansing et al. [24] included travellers
and rectal swabs, whereof one isolate was Citrobacter
freundii, and Platteel et al. [25] analysed perianal and
faeces swabs from patients admitted to the hospital. The
study population of Star-SHL is most comparable with
the population of NethMap, i.e. urine samples of pa-
tients from GPs submitted mostly after treatment failure.
However, we only included E. coli and K. pneumoniae
to determine the prevalence of ESBL, whereas
NethMap’s ESBL prevalence was based on isolates of
all Enterobacteriaceae. One would expect a higher
E S B L - p r e v a l e n c e w h e n i n c l u d i n g a l l
Enterobacteriaceae, but this was not the case.
Nitrofurantoin is the first choice for treating UTI according
to the NHG guidelines [3]. Although the prevalence of
nitrofurantoin resistance was low in Rotterdam and at the na-
tional level, we found that resistance in the age group of ≥
70 years was higher than in the group < 70 years (OR 4.11;
95% CI 1.50–14.41; p = 0.01). After correction for multiple
testing, this association was not statistically significant, but an
impaired kidney function, which often occurs in the elderly,
can make nitrofurantoin less effective in this age group [26].
Therefore, caution is needed when prescribing nitrofurantoin
to older patients.
Table 3 Factors associated with resistant E. coli in 2016 (n = 1130) using univariate logistic regression analysis
Age ≥ 70 years
versus < 70 years
Female vs. male Low SES score vs. high SES score Middle SES score vs. high SES
score
Antibiotic OR 95% CI p OR 95% CI p OR 95% CI p OR 95% CI p
Nitrofurantoina 4.11* 1.50–14.41 0.01 1.00 0.33–4.30 1.00 NAb NAb NAb NAb NAb NAb
Fosfomycina 2.34 0.99–6.12 0.06 3.94 0.82–70.73 0.18 1.92 0.38–34.79 0.53 1.45 0.24–27.53 0.73
Trimethoprima 1.20 0.92–1.57 0.18 1.13 0.78–1.68 0.52 0.77 0.47–1.29 0.31 0.87 0.52–1.48 0.59
Co-trimoxazole 1.10 0.83–1.44 0.51 1.22 0.83–1.84 0.32 0.82 0.50–1.39 0.45 0.85 0.50–1.48 0.55
Amoxicillin 1.12 0.88–1.41 0.36 0.94 0.68–1.31 0.71 0.77 0.49–1.22 0.26 0.78 0.48–1.26 0.30
Co-amoxiclav 1.14 0.84–1.54 0.41 0.88 0.59–1.35 0.54 1.19 0.66–2.31 0.56 1.11 0.59–2.21 0.76
Cefuroxime 1.15 0.76–1.75 0.51 1.14 0.64–2.18 0.68 4.93* 1.51 – 30.35 0.03 2.62 0.75–16.57 0.20
Ciprofloxacin 1.86* 1.27–2.73 0.001c 0.69 0.44 - 1.13 0.13 1.48 0.70–3.62 0.34 0.99 0.44–2.54 0.99
SES social economic status
*Statistically significant associations
a These antibiotics should be prescribed in this order (first, second and third choice) by the GPs according to the National Guideline for UTI [23]
bNA not applicable: too few outcome events (high SES score has 0 resistant E. coli to nitrofurantoin)
c Significant after adjustment for multiple testing using the Holm-Bonferroni method, p = 0.03
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Females are known to be more prone to UTIs than males
[27, 28]. A UTI in females is usually uncomplicated without
tissue invasion, whereas in males it is more often complicated
because of prostate involvement [3]. Treatment for an uncom-
plicated UTI includes agents that give high concentrations in
the urine, such as nitrofurantoin and fosfomycin. For males,
the agents need to reach a sufficiently high concentration in
the prostate, such as co-trimoxazole and ciprofloxacin.
Although our study sample contained more women than
men, there were enough men in our analysis when comparing
resistance in men versus women (20.0%, n = 347). We found
no differences in the prevalence of resistance of these last two
agents between males and females and therefore concluded
that gender was not a risk factor for resistance in our study.
In conclusion, the prevalence of AMR in the
Rotterdam region is low. This indicates that adherence
to national guidelines in general practice enables main-
tenance of low AMR, even in high-risk populations. To
explore the associations between migration, socioeco-
nomic factors, and AMR, these variables need to be
included in further studies.
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